Daiichi Sankyo's HER3-Targeted ADC U3-1402 Granted Clinical Trial Approval in China for Non-Small Cell Lung Cancer

On July 13, the official website of the CDE indicated that Daiichi Sankyo’s novel HER3-targeting ADC U3-1402 has been approved for clinical trials for the treatment of non-small cell lung cancer.

U3-1402 is an investigational antibody-drug conjugate developed by Daiichi Sankyo. Its antibody component is the HER3 monoclonal antibody patritumab (U3-1287), which is covalently conjugated via a linker to the topoisomerase I inhibitor exatecan (MAAA-1181a), with each antibody molecule conjugated to 8 exatecan molecules. Upon binding to HER3 on the surface of cancer cells, U3-1402 is internalized, resulting in the intracellular release of exatecan, thereby exerting cytotoxic effects to eliminate cancer cells.